Abstract
Fibulin-3 (F3) is a secreted, disulfide-rich glycoprotein which is expressed in a variety of tissues within the body, including the retina. An Arg345Trp (R345W) mutation in F3 was identified as the cause of a rare retinal dystrophy, Malattia Leventinese/Doyne Honeycomb Retinal Dystrophy (ML/DHRD). ML/DHRD shares many phenotypic similarities with age-related macular degeneration (AMD). The most prominent feature of ML/DHRD is the development of radial or honeycomb patterns of drusen which can develop as early as adolescence. Two independent mouse models of ML/DHRD show evidence of complement activation as well as retinal pigment epithelium (RPE) atrophy, strengthening the phenotypic connection with AMD. Because of its similarities with AMD, ML/DHRD is receiving increasing interest as a potential surrogate disease to study the underpinnings of AMD. This mini-review summarizes the current knowledge of F3 and points toward potential therapeutic strategies which directly or indirectly target cellular dysfunction associated with R345W F3.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Fu L, Garland D, Yang Z et al (2007) The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice. Hum Mol Genet 16:2411–2422
Garland DL, Fernandez-Godino R, Kaur I et al (2014) Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. Hum Mol Genet 23:52–68
Hulleman JD, Kelly JW (2015) Genetic ablation of N-linked glycosylation reveals two key folding pathways for R345W fibulin-3, a secreted protein associated with retinal degeneration. FASEB J 29:565–575
Hulleman JD, Kaushal S, Balch WE et al (2011) Compromised mutant EFEMP1 secretion associated with macular dystrophy remedied by proteostasis network alteration. Mol Biol Cell 22:4765–4775
Hulleman JD, Balch WE, Kelly JW (2012) Translational attenuation differentially alters the fate of disease-associated fibulin proteins. FASEB J 26:4548–4560
Hulleman JD, Brown SJ, Rosen H et al (2013) A high-throughput cell-based Gaussia luciferase reporter assay for identifying modulators of fibulin-3 secretion. J Biomol Screen 18:647–658
Jessop CE, Chakravarthi S, Garbi N et al (2007) ERp57 is essential for efficient folding of glycoproteins sharing common structural domains. EMBO J 26:28–40
Klein ML, Schultz DW, Edwards A et al (1998) Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol 116:1082–1088
Klenotic PA, Munier FL, Marmorstein LY et al (2004) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. The J Biol Chem 279:30469–30473
Lenassi E, Troeger E, Wilke R et al (2013) Laser clearance of drusen deposit in patients with autosomal dominant drusen (p.Arg345Trp in EFEMP1). Am J Ophthalmol 155:190–198
Marmorstein LY, Munier FL, Arsenijevic Y et al (2002) Aberrant accumulation of EFEMP1 underlies drusen formation in malattia leventinese and age-related macular degeneration. Proc Natl Acad Sci U S A 99:13067–13072
Marmorstein LY, McLaughlin PJ, Peachey NS et al (2007) Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration. Hum Mol Genet 16:2423–2432
McLaughlin PJ, Bakall B, Choi J et al (2007) Lack of fibulin-3 causes early aging and herniation, but not macular degeneration in mice. Hum Mol Genet 16:3059–3070
Michaelides M, Jenkins SA, Brantley MA Jr et al (2006) Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction. Invest Ophthalmol Vis Sci 47:3085–3097
Oka OB, Pringle MA, Schopp IM et al (2013) ERdj5 is the ER reductase that catalyzes the removal of non-native disulfides and correct folding of the LDL receptor. Mol Cell 50:793–804
Parodi MB, Virgili G, Evans JR (2009) Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev 8(3):CD006537
Ricklin D, Lambris JD (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol 632:273–292
Roybal CN, Marmorstein LY, Vander Jagt DL et al (2005) Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression. Invest Ophthalmol Vis Sci 46:3973–3979
Ruggiano A, Foresti O, Carvalho P (2014) Quality control: ER-associated degradation: protein quality control and beyond. J Cell Biol 204:869–879
Schultz DW, Weleber RG, Lawrence G et al (2005) HEMICENTIN-1 (FIBULIN-6) and the 1q31 AMD locus in the context of complex disease: review and perspective. Ophthalmic Genet 26:101–105
Sercu S, Lambeir AM, Steenackers E et al (2009) ECM1 interacts with fibulin-3 and the beta 3 chain of laminin 332 through its serum albumin subdomain-like 2 domain. Matrix Biol 28:160–169
Shoulders MD, Ryno LM, Genereux JC et al (2013) Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep 3:1279–1292
Sohn EH, Wang K, Thompson S et al (2014) Comparison of drusen and modifying genes in autosomal dominant radial drusen and age-related macular degeneration. Retina 35(1):48-57
Stone EM, Lotery AJ, Munier FL et al (1999) A single EFEMP1 mutation associated with both malattia leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 22:199–202
Stone EM, Braun TA, Russell SR et al (2004) Missense variations in the fibulin 5 gene and age-related macular degeneration. N Engl J Med 351:346–353
Thompson CL, Klein BE, Klein R et al (2007) Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes. Hum Mol Genet 16:2135–2148
Wyatt MK, Tsai JY, Mishra S et al (2013) Interaction of complement factor h and fibulin3 in age-related macular degeneration. PLoS ONE 8:e68088
Acknowledgments
This work was funded by an endowment from the Roger and Dorothy Hirl Research Fund, an NEI core grant (EY020799), a career development award from Research to Prevent Blindness (RPB), and an unrestricted grant from RPB. The author thanks Bonnie Miller and Rafael Ufret-Vincenty for their review of this manuscript
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Hulleman, J. (2016). Malattia Leventinese/Doyne Honeycomb Retinal Dystrophy: Similarities to Age-Related Macular Degeneration and Potential Therapies. In: Bowes Rickman, C., LaVail, M., Anderson, R., Grimm, C., Hollyfield, J., Ash, J. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 854. Springer, Cham. https://doi.org/10.1007/978-3-319-17121-0_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-17121-0_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17120-3
Online ISBN: 978-3-319-17121-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)